Experts at last week's BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they'd be more cost-effective.
Can we think of a less innovative word these days than "innovative?" BIO doesn't seem to care, given its hackneyed new name change.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
More evidence that Minnesota has a lot of work to do in developing a viable biotech industry. From 2004 to 2009, local human biotech firms attracted only $1 million in venture capital compared to $1.2 billion for medical devices, according to a report by Battelle Memorial Institute and the Biotechnology Industry Organization. $1 million over […]
The Biotechnology Industry Organization international convention returns to Chicago this week — a nod to the importance of pharmaceutical and therapeutic companies in Midwestern states like Ohio. Drugmaking has history in Ohio. From Procter & Gamble Pharmaceuticals (NYSE: PG) in Cincinnati (sold last year to Irish drug company Warner Chilcott), to generic drugmakers Ben Venue […]
University/industry research and development partnerships added $187 billion to the U.S. economy from 1996 to 2007, according to a Biotechnology Industry Organization study of the affects of the Bayh-Dole Act.
So is the nation's biotechnology industry booming or a bust? It all depends on where you are.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Even the "recession-proof" health care and biotechnology industries are feeling the economic pain of the worst contraction since The Big One. Will consumers keep the health care industry growing?